Basal Cell Carcinoma: Mohs Indications & Treatment
Basal cell carcinoma (BCC) is the most common malignancy in humans, with over 4 million cases diagnosed annually in the United States alone. While BCC rarely metastasizes, locally aggressive subtypes can cause significant tissue destruction if inadequately treated. This article reviews BCC histopathologic subtypes, NCCN v1.2026 risk stratification criteria, indications for Mohs micrographic surgery, AUC guidelines, and the treatment algorithm from low-risk to advanced disease.
By Dr. Yehonatan Kaplan (M.D., Fellow ACMS)·Published: 2025-03-01·Updated: 2026-03-15·Reviewed: 2026-03-07
BCCbasal cell carcinomaMohs surgeryNCCN guidelinesskin cancerhedgehog inhibitor
Key Takeaways
- BCC is the most common human malignancy, accounting for ~80% of all nonmelanoma skin cancers, with over 4 million cases annually in the US.
- Mohs micrographic surgery achieves a 99% 5-year cure rate for primary BCC and ~93-95% for recurrent BCC - the highest of any treatment modality.
- Any single NCCN high-risk criterion (H-zone location, aggressive subtype, recurrence, PNI, immunosuppression) upgrades the entire tumor to high-risk.
- Aggressive subtypes (infiltrative, morpheaform, micronodular, basosquamous) can extend 3-7mm beyond clinical margins - Mohs is critical for margin control.
- Hedgehog pathway inhibitors (vismodegib, sonidegib) and anti-PD-1 immunotherapy (cemiplimab) provide options for locally advanced BCC not amenable to surgery.
- Patients with one BCC have a 36-50% risk of developing another within 5 years - long-term surveillance every 6-12 months is essential.
Overview & Epidemiology
Basal cell carcinoma is the most common human malignancy and accounts for approximately 80% of all nonmelanoma skin cancers. The incidence continues to rise worldwide, driven primarily by cumulative ultraviolet radiation exposure, indoor tanning, and an aging population. Fair-skinned individuals (Fitzpatrick skin types I-II) are at greatest risk, with the highest incidence in Australia, followed by the United States and Europe. BCC typically presents in the sixth and seventh decades of life, though an increasing number of cases are being diagnosed in younger patients. The male-to-female ratio has historically been approximately 2:1, but this gap has been narrowing in recent decades. Risk factors beyond UV exposure include immunosuppression, prior radiation therapy, genetic syndromes (basal cell nevus/Gorlin syndrome, xeroderma pigmentosum), arsenic exposure, and chronic inflammatory skin conditions. Despite its high incidence, BCC carries a metastatic rate of less than 0.1%, making it a locally destructive but rarely lethal malignancy.
Histopathologic Subtypes
BCC is classified into multiple histopathologic subtypes, each carrying distinct biologic behavior and implications for treatment selection. The subtype is one of the most important factors in determining recurrence risk and the appropriateness of Mohs surgery. Nodular BCC is the most common subtype, representing approximately 60-80% of all BCCs. It is characterized by well-circumscribed islands of basaloid cells with peripheral palisading and retraction artifact, and is generally considered low-risk when other high-risk features are absent. Superficial BCC accounts for 10-15% of cases and is characterized by multifocal nests of basaloid cells budding from the epidermis, without significant dermal invasion. Infiltrative and morpheaform subtypes are the most clinically significant aggressive variants, characterized by thin cords and strands of tumor cells extending irregularly through the dermis with extensive subclinical extension. These aggressive subtypes frequently extend well beyond clinical margins and have the highest recurrence rates with standard excision.
| Subtype | Frequency | Growth Pattern | Risk Level | Clinical Significance |
|---|---|---|---|---|
| Nodular | 60-80% | Well-circumscribed islands with peripheral palisading | Low (when isolated) | Most common; generally well-defined clinically; favorable for standard excision in L-zone |
| Superficial | 10-15% | Multifocal buds from epidermis, minimal dermal invasion | Low | Often multifocal; may extend laterally beyond clinical borders; amenable to superficial therapies |
| Infiltrative | 5-10% | Thin, irregular cords and strands invading dermis | High | Aggressive; extensive subclinical extension; poorly defined clinical borders; Mohs strongly indicated |
| Morpheaform (sclerosing) | 2-5% | Dense sclerotic stroma with thin tumor strands | High | Most aggressive subtype; scar-like clinical appearance; highest subclinical extension; Mohs critical |
| Micronodular | 5-15% | Small nodular aggregates widely dispersed in dermis | High | Frequently extends beyond clinical margins; often mixed with other subtypes; Mohs preferred |
| Basosquamous (metatypical) | 1-2% | Features of both BCC and SCC differentiation | High | Higher metastatic potential than standard BCC; more aggressive behavior; treat as high-risk |
Dermoscopy of BCC
Dermoscopy significantly improves diagnostic accuracy for BCC compared to clinical examination alone. BCC dermoscopic features reflect the tumor vasculature, pigmentation pattern, and stromal changes. The hallmark finding is the absence of a pigment network (which is present in melanocytic lesions) combined with one or more BCC-specific criteria. Dermoscopy also provides valuable information about histopathologic subtype, which can guide the decision between Mohs surgery and other treatment modalities.
Classic Dermoscopic Criteria
Six classic dermoscopic features are associated with BCC: (1) Arborizing (tree-like) vessels, branching telangiectasias with sharp-focused, thick-stemmed vessels that dichotomize into finer branches, reflecting the tumor vasculature. This is the most specific dermoscopic finding for BCC. (2) Large blue-gray ovoid nests, well-circumscribed, ovoid structures larger than globules, representing dermal aggregates of pigmented tumor cells. (3) Leaf-like areas (maple leaf-like structures), brown-to-gray bulbous projections connected at a common base, found at the periphery of the lesion, corresponding to pigmented tumor nests. (4) Spoke-wheel areas, well-circumscribed radial projections meeting at a central darker axis, corresponding to nests of basaloid cells surrounded by stroma. (5) Ulceration, not specific to BCC alone but common, particularly in nodular BCC. (6) Short fine superficial telangiectasias, thin, short, and poorly focused vessels associated with superficial BCC subtype.
Dermoscopy by BCC Subtype
Different BCC subtypes exhibit distinct dermoscopic patterns that correlate with their histopathologic architecture. Nodular BCC typically shows arborizing vessels (the dominant feature), large blue-gray ovoid nests, and ulceration. Superficial BCC demonstrates short fine telangiectasias (rather than the thick arborizing pattern), multiple small erosions, and leaf-like/spoke-wheel structures at the periphery; shiny white-red structureless areas are also characteristic. Pigmented BCC adds blue-gray globules, blue-gray ovoid nests, and brown-black spoke-wheel or leaf-like structures to the baseline pattern. Morpheaform/infiltrative BCC may show arborizing vessels, white-red structureless areas, and poorly defined borders with few classic pigmented criteria, reflecting its sclerotic stroma and limited pigment production.
| BCC Subtype | Dominant Vascular Pattern | Pigmented Structures | Other Features |
|---|---|---|---|
| Nodular | Arborizing (tree-like) vessels; thick stem, sharp focus | Blue-gray ovoid nests, globules | Ulceration, shiny white structures (chrysalis) |
| Superficial | Short fine superficial telangiectasias; thin, poorly focused | Leaf-like areas, spoke-wheel areas | Multiple small erosions, shiny white-red structureless areas |
| Pigmented | Variable (follows baseline subtype) | Blue-gray ovoid nests, globules, maple-leaf areas | Absence of pigment network (distinguishes from melanoma) |
| Morpheaform/Infiltrative | Arborizing vessels (may be subtle) | Few or absent pigmented structures | White-red structureless areas, poorly defined borders |
Dermoscopy in Mohs Planning
Dermoscopy can assist preoperative margin assessment for BCC. Studies have demonstrated that dermoscopic tumor borders may extend beyond clinically visible margins, particularly in superficial and morpheaform subtypes. Marking margins under dermoscopic guidance before Mohs surgery may reduce the number of stages required. Dermoscopy is also valuable for monitoring response to nonsurgical treatments (imiquimod, 5-fluorouracil, photodynamic therapy) for superficial BCC; resolution of dermoscopic criteria correlates with histologic clearance.
NCCN Risk Stratification (v1.2026)
The National Comprehensive Cancer Network (NCCN) guidelines v1.2026 stratify BCCs into low-risk and high-risk categories based on a combination of clinical and pathologic features. This risk stratification directly determines the recommended treatment algorithm. The system integrates anatomic location (using the H/M/L zone system), tumor size, histopathologic subtype, clinical features, and patient factors. A tumor is classified as high-risk if it meets any single high-risk criterion. All criteria must be low-risk for the tumor to be classified as low-risk. This conservative approach ensures that potentially aggressive tumors are not undertreated. The H-zone encompasses the "mask areas" of the face where recurrence rates are highest and tissue conservation is most critical: central face, eyelids, eyebrows, periorbital, nose, lips, chin, mandible, preauricular and postauricular skin, temple, ear, and genitalia. The M-zone includes the cheeks, forehead, scalp, neck, jawline, pretibial area, hands, and feet. The L-zone covers the trunk and extremities excluding the pretibial, hands, and feet. The NCCN risk stratification is the foundation for determining whether Mohs surgery is indicated.
| Feature | Low Risk | High Risk |
|---|---|---|
| Location/Size | L-zone <20mm; M-zone <10mm | L-zone >=20mm; M-zone >=10mm; H-zone any size |
| Borders | Well-defined | Poorly defined |
| Primary vs. Recurrent | Primary | Recurrent |
| Immunosuppression | No | Yes |
| Prior RT at site | No | Yes |
| Subtype (histology) | Nodular, superficial | Infiltrative, morpheaform/sclerosing, micronodular, basosquamous, BCC with squamous differentiation |
| Perineural involvement | No | Yes |
Indications for Mohs Micrographic Surgery
Mohs micrographic surgery is the treatment of choice for high-risk BCCs as defined by NCCN guidelines. The technique provides the highest cure rate (99% for primary BCC, 94-95% for recurrent BCC) while maximizing tissue conservation through complete circumferential and deep margin assessment. Mohs is indicated for BCCs classified as high-risk by any criterion, including those in the H-zone (central face, eyelids, nose, lips, ears, temple, periauricular, genitalia), recurrent or incompletely excised tumors, aggressive histologic subtypes (infiltrative, morpheaform, micronodular, basosquamous), tumors with perineural invasion, tumors in immunosuppressed patients, and tumors arising in previously irradiated skin. Beyond NCCN criteria, Mohs is also indicated when maximal tissue conservation is critical for functional or cosmetic outcomes, regardless of strict risk classification. The dual role of the Mohs surgeon as both surgeon and pathologist ensures real-time, intraoperative margin control. The reconstruction is performed only after 100% margin clearance is confirmed.
Location-Based Indications
The H-zone represents the strongest location-based indication for Mohs surgery. BCCs in the H-zone. The central face, periorbital area, eyelids, nose, lips, chin, ears, temple, and periauricular region. Have the highest recurrence rates with standard excision due to complex anatomic contours, proximity to vital structures, and the need for maximal tissue conservation. Even small, well-defined, nodular BCCs in the H-zone benefit from Mohs because the tissue-sparing advantage can mean the difference between primary closure and a flap or graft reconstruction. The genitalia are also classified as H-zone, though BCCs in this location are uncommon. M-zone locations (cheeks, forehead, scalp, neck, pretibial, hands, feet) warrant Mohs when additional high-risk features are present, such as aggressive subtype, recurrence, or large size.
Tumor-Feature-Based Indications
Aggressive histologic subtypes (infiltrative, morpheaform, micronodular, basosquamous) are among the strongest indications for Mohs regardless of location. These subtypes have extensive subclinical extension that is frequently underestimated by clinical examination, leading to unacceptably high recurrence rates with standard excision using predetermined margins. Recurrent BCCs. Tumors that have returned after prior treatment. Develop scar tissue that disrupts normal tissue planes and creates irregular, unpredictable tumor extensions. Incompletely excised BCCs (positive margins on prior excision) present a similar challenge, as the residual tumor distribution is impossible to predict clinically after surgical disruption. Perineural invasion on biopsy indicates a propensity for along-nerve extension, and these tumors require the meticulous margin assessment that only Mohs can provide.
AUC Criteria for Mohs Surgery
The Appropriate Use Criteria (AUC) published by the AAD and ACMS provide a standardized framework for determining when Mohs surgery is considered appropriate, uncertain, or inappropriate for BCC treatment. The AUC system evaluates clinical scenarios based on the combination of anatomic location (Areas H, M, L), tumor characteristics (size, subtype, recurrence status), and patient factors (immunosuppression). For BCC in Area H, Mohs is rated as appropriate for virtually all scenarios regardless of size, subtype, or recurrence status. In Area M, Mohs is appropriate when additional risk factors are present, such as aggressive subtype, recurrence, large size, or immunosuppression. In Area L, Mohs is generally appropriate only for recurrent tumors, incompletely excised tumors, or those with multiple high-risk features. The AUC system aligns closely with NCCN guidelines but provides more granular scenario-based recommendations. Proper AUC documentation strengthens clinical justification and supports insurance authorization for the procedure.
Treatment Algorithm
The NCCN v1.2026 treatment algorithm for BCC is stratified by risk level. For low-risk BCCs, multiple treatment options exist with comparable outcomes, and the choice depends on location, patient preference, and clinical context. For high-risk BCCs, Mohs micrographic surgery is the preferred treatment when available, with wide local excision with complete circumferential peripheral and deep margin assessment (CCPDMA) as an alternative when Mohs is not accessible.
Low-Risk BCC Treatment Options
Low-risk BCCs (small, well-defined, nodular or superficial subtype, in M-zone or L-zone, primary, non-immunosuppressed) can be managed with several effective modalities. Standard surgical excision with 4mm clinical margins achieves 95-96% cure rates for primary nodular BCC. Curettage and electrodesiccation (C&E) is an acceptable option for small, well-defined, nodular BCCs on the trunk and extremities, with cure rates of 92-97% when performed with appropriate technique (typically 2-3 cycles). Superficial BCCs specifically may be treated with topical imiquimod 5% (5 times weekly for 6 weeks), topical 5-fluorouracil (5-FU), or photodynamic therapy (PDT), though these nonsurgical options carry higher recurrence rates (5-20% depending on modality). Radiation therapy is reserved for patients who are not surgical candidates. Cryosurgery is an option only for small, well-defined, low-risk BCCs in select patients.
High-Risk BCC Treatment Options
High-risk BCCs require treatment modalities that provide the highest margin control. Mohs micrographic surgery is the preferred treatment for high-risk BCC per NCCN v1.2026 guidelines, achieving 99% cure rates for primary and approximately 93-95% for recurrent disease. When Mohs is not available, standard excision with wider margins (minimum 4mm, often extended to 5-10mm for aggressive subtypes) with CCPDMA is the recommended alternative. CCPDMA refers to complete circumferential peripheral and deep margin assessment. Histologic processing that evaluates the entire margin similar to Mohs, but performed on permanent (formalin-fixed, paraffin-embedded) sections rather than frozen sections. Radiation therapy may be considered as adjuvant treatment for high-risk BCCs with perineural invasion or positive margins that cannot be re-excised. Standard excision without CCPDMA using traditional bread-loaf processing is not recommended for high-risk BCC due to the high rate of margin sampling error.
Advanced & Metastatic BCC
Locally advanced BCC (laBCC) refers to tumors that are not amenable to surgery or radiation due to size, location, or extent of invasion. Metastatic BCC is exceedingly rare (<0.1% of all BCCs) but carries a poor prognosis when it occurs. The Hedgehog (Hh) signaling pathway is constitutively activated in the vast majority of BCCs, primarily through loss-of-function mutations in PTCH1 or gain-of-function mutations in SMO. This molecular understanding has led to the development of targeted therapies that have transformed the management of advanced BCC. Vismodegib (Erivedge) was the first FDA-approved Hedgehog pathway inhibitor, demonstrating a 30% complete response rate and 43% partial response rate in laBCC. Sonidegib (Odomzo) is the second-generation Hh inhibitor with similar efficacy. Both agents are associated with significant side effects including muscle spasms, alopecia, dysgeusia, weight loss, and fatigue, which limit tolerability and lead to treatment discontinuation in 20-50% of patients. More recently, cemiplimab (Libtayo), an anti-PD-1 immune checkpoint inhibitor, received FDA approval for laBCC after Hedgehog inhibitor therapy, demonstrating durable responses in approximately 30% of patients.
Prognosis & Follow-up
The prognosis for BCC is excellent when appropriately managed. Mohs micrographic surgery achieves 5-year cure rates of 99% for primary BCC and approximately 93-95% for recurrent BCC (Leibovitch et al. 2005: 93.3%), the highest of any treatment modality. Standard excision with adequate margins achieves 95-96% 5-year cure rates for primary nodular BCC. However, patients who have had one BCC are at significantly elevated risk for developing additional BCCs. The 5-year risk of a subsequent BCC is approximately 36-50%. This high rate of new primary tumors necessitates long-term dermatologic surveillance. NCCN v1.2026 recommends follow-up examinations every 6-12 months for the first 2 years after treatment, then annually thereafter, with full skin examinations at each visit. Patients with multiple BCCs, aggressive subtypes, or immunosuppression may warrant more frequent surveillance (every 3-6 months). Patient education regarding sun protection, self-examination, and early recognition of new lesions is an essential component of follow-up care.
| Treatment Modality | 5-Year Cure Rate (Primary) | 5-Year Cure Rate (Recurrent) |
|---|---|---|
| Mohs micrographic surgery | 99% | ~93-95% |
| Standard excision (adequate margins) | 95-96% | 82-90% |
| Curettage & electrodesiccation | 92-97% | Not recommended |
| Radiation therapy | 90-93% | 85-90% |
| Cryosurgery | 85-95% | Not recommended |
Frequently Asked Questions
Related Articles
Recent Evidence
From the Northwestern Medicine Dermatologic Surgery Journal Club
Peillex D, Passemard L, Magnin B, et al. · Dermatol Surg (2022)
Metastatic BCC - Real-World Analysis of Risk Factors, Therapeutics, and Outcomes
Schapiro S, Pulciano N, Galindo-Ramirez J, et al. · Dermatologic Surgery (2026)
Gorlin Syndrome (NBCCS) - Updated Clinical Management Guidelines
Mitropoulos P, Norman R · Journal of the American Academy of Dermatology (JAAD) (2008)
References
- [1]National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Basal Cell Skin Cancer v1.2026. NCCN Guidelines. 2026.
- [2]Robinson JK, Hanke CW, Siegel DM, Fratila A. Surgery of the Skin: Procedural Dermatology, 3rd Edition. Elsevier. 2019.
- [3]Chen ELA, Srivastava D, Nijhawan RI. Mohs Micrographic Surgery: Development, Technique, and Applications in Cutaneous Malignancies. Semin Plast Surg. 2018. doi:10.1055/s-0038-1642057 PMID: 29765269
- [4]Leibovitch I, Huilgol SC, Selva D, et al. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J Am Acad Dermatol. 2005. doi:10.1016/j.jaad.2004.09.052 PMID: 15793512
- [5]Dummer R, Guminski A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020. doi:10.1111/bjd.18552 PMID: 31545507
- [6]Lallas A, Apalla Z, Argenziano G, et al. The dermatoscopic universe of basal cell carcinoma. Dermatol Pract Concept. 2014. doi:10.5826/dpc.0403a02 PMID: 25126452
- [7]Lallas A, Argenziano G, Zendri E, et al. Update on non-melanoma skin cancer and the value of dermoscopy in its diagnosis and treatment monitoring. Expert Rev Anticancer Ther. 2013. doi:10.1586/era.13.38 PMID: 23617346
- [8]sekulic-2012-vismodegib-bcc
- [9]kim-2019-bcc-mohs-recurrence
- [10]wain-2019-bcc-margin-control
- [11]nehal-2018-bcc-update
- [12]Connolly SM, Baker DR, Coldiron BM, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery. J Am Acad Dermatol. 2012. doi:10.1016/j.jaad.2012.06.009 PMID: 22959232
About This Article
Author: Dr. Yehonatan Kaplan, M.D., Fellow ACMS
Last Medical Review:
Audience: Dermatologic Surgeons
Clinic: Kaplan Clinic · DermUnbound Research Program